Results 41 to 50 of about 17,784 (227)

An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough. [PDF]

ERJ Open Res, 2021
Blocking NMDA receptors with memantine in refractory chronic cough patients is poorly tolerated and demonstrates no improvement in cough https://bit.ly/3kgx2g1.
Abdulqawi R, Satia I, Holt KJ, Dockry R, Sen S, Smith JA.   +5 more
europepmc   +2 more sources

Heterogeneity of cough hypersensitivity mediated by TRPV1 and TRPA1 in patients with chronic refractory cough

Respiratory Research, 2019
Background The differential sensitivity of cough to antitussive therapies implies the existence of heterogeneity in cough hypersensitivity, but how such heterogeneity is expressed across individual patients is poorly understood.
Li Long, Hongmei Yao, Jing Tian, Wei Luo, Xinxin Yu, Fang Yi, Qiaoli Chen, Jiaxing Xie, Nanshan Zhong, Kian Fan Chung, Kefang Lai   +10 more
doaj   +1 more source

New insights in the diagnosis of chronic refractory cough [PDF]

Respiratory Medicine, 2018
Chronic Refractory Cough (CRC) is a common condition that significantly impairs patients' quality of life. Unfortunately, in many situations patients continue to experience CRC in spite of following published guidelines for diagnosis and treatment.99 patients were referred to National Jewish Health (NJH), a specialty respiratory center for evaluation ...
James T, Good, Donald R, Rollins, Christena A, Kolakowski, Allen D, Stevens, Joshua L, Denson, Richard J, Martin   +5 more
openaire   +2 more sources

The Severity of Chronic Cough Diary (SCCD): development and content validation of a novel patient-reported outcome instrument for evaluating the symptom experience of chronic cough

Journal of Patient-Reported Outcomes, 2023
Background Refractory chronic cough (RCC), a cough lasting longer than 8 weeks with an unexplained underlying etiology and unresponsive to conventional treatment, can have substantial effects on patients’ quality of life.
Margarita de la Orden Abad, Claudia Haberland, Hayley Karn, Anne Skalicky, Asha Hareendran   +4 more
doaj   +1 more source

Non-pharmacological interventions for chronic cough: the past, present and future [PDF]

, 2019
Non-pharmacological interventions have been explored in people with refractory chronic cough. Normally delivered by Physiotherapists and or Speech and Language Therapists, these interventions aim to educate patients about their cough, provide them with ...

core   +1 more source

WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care. Updates in COVID-19

, 2022
Background Chronic cough management necessitates a clear integrated care pathway approach. Primary care physicians initially encounter the majority of chronic cough patients, yet their role in proper management can prove challenging due to limited ...
Azar, Cecilio R, Scadding, Glenis K, Laidlaw, Tanya M, Bahna, Sami L, Al-Ahmad, Mona S, Al-Nesf, Maryam Ali Y, Nsouli, Talal M, Idriss, Samar A, Rouadi, Philip W, Hellings, Peter W, Zaitoun, Fares H, Abou-Jaoude, Eliane, Hadi, Usamah M, Yanez, Anahi, Bousquet, Jean, et al.   +15 more
core   +1 more source

Europe's contribution to the evaluation of the use of systemic antimicrobials in the treatment of periodontitis

Periodontology 2000, EarlyView., 2023
Abstract This narrative review celebrates Europe's contribution to the current knowledge on systemically administered antimicrobials in periodontal treatment. Periodontitis is the most frequent chronic noncommunicable human disease. It is caused by dysbiotic bacterial biofilms and is commonly treated with subgingival instrumentation.
David Herrera, Arie Jan van Winkelhoff, Paula Matesanz, Katalina Lauwens, Wim Teughels   +4 more
wiley   +1 more source

Efficacy and safety of gefapixant, a P2X₃ receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

, 2022
Background: Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough.
Marsden, Paul; id_orcid
core   +3 more sources

Treatment of recalcitrant cough with baclofen

Italian Journal of Medicine, 2013
Background: Chronic dry cough is a debilitating symptom often refractory to standard antitussive therapy. It may result from increased sensitivity of the cough reflex. Baclofen, an agonist of gamma-aminobutyric acid (GABA), has been shown, in animals, to
Paolo Agostinis, Paola Bardus, Vito Di Piazza, Ferdinando Dassi, Nadia Durigon, Alfio Englaro, Patrizia Grillo, Euro Marchetti, Tiziano Petris, Enzo Sabatini   +9 more
doaj   +1 more source

Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework

European Respiratory Review, 2021
Background Cough severity represents an important subjective endpoint in assessing the effectiveness of therapies for patients with chronic cough. Although cough-specific quality of life questionnaires exist, a widely available cough severity instrument ...
Elena Kum, Gordon H. Guyatt, Tahira Devji, Yuting Wang, Layla Bakaa, Lucy Lan, Eva Liu, Alexander Mastrolonardo, Rachel Couban, Paul M. O'Byrne, Imran Satia   +10 more
doaj   +1 more source